- Home
- HTGC vs AKRO Comparison
HTGC vs AKRO Comparison
Compare HTGC & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTGC
- AKRO
- Stock Information
- Founded
- HTGC 2003
- AKRO 2017
- Country
- HTGC United States
- AKRO United States
- Employees
- HTGC N/A
- AKRO N/A
- Industry
- HTGC Investment Managers
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- HTGC Finance
- AKRO Health Care
- Exchange
- HTGC Nasdaq
- AKRO Nasdaq
- Market Cap
- HTGC 3.5B
- AKRO 3.6B
- IPO Year
- HTGC 2005
- AKRO 2019
- Fundamental
- Price
- HTGC $19.20
- AKRO $42.18
- Analyst Decision
- HTGC Buy
- AKRO Strong Buy
- Analyst Count
- HTGC 8
- AKRO 8
- Target Price
- HTGC $21.31
- AKRO $80.38
- AVG Volume (30 Days)
- HTGC 770.5K
- AKRO 915.6K
- Earning Date
- HTGC 10-29-2025
- AKRO 11-07-2025
- Dividend Yield
- HTGC 9.80%
- AKRO N/A
- EPS Growth
- HTGC N/A
- AKRO N/A
- EPS
- HTGC 1.52
- AKRO N/A
- Revenue
- HTGC $504,002,000.00
- AKRO N/A
- Revenue This Year
- HTGC $8.25
- AKRO N/A
- Revenue Next Year
- HTGC $7.47
- AKRO N/A
- P/E Ratio
- HTGC $12.65
- AKRO N/A
- Revenue Growth
- HTGC 3.72
- AKRO N/A
- 52 Week Low
- HTGC $15.65
- AKRO $21.34
- 52 Week High
- HTGC $22.04
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- HTGC 48.11
- AKRO 33.17
- Support Level
- HTGC $19.07
- AKRO $41.77
- Resistance Level
- HTGC $19.62
- AKRO $45.44
- Average True Range (ATR)
- HTGC 0.22
- AKRO 1.77
- MACD
- HTGC -0.03
- AKRO -0.22
- Stochastic Oscillator
- HTGC 23.64
- AKRO 5.66
About HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.